Britse verpleegkundigen en de zorg voor mesothelioompatiënten

03-10-2007

Een artikel in het Britse blad Nursing Standard beschrijft de specifieke uitdagingen voor verpleegkundigen bij de zorg van mesothelioompatiënten, een groep waarmee zij steeds meer in aanraking komen omdat het aantal patiënten nog steeds toeneemt. Maligne mesothelioom vereist een speciale aanpak omdat de ziekte zowel medische als juridische gevolgen heeft. In het Verenigd Koninkrijk moet de ziekte bijvoorbeeld gemeld worden bij de politie. Er bestaan geen nationale richtlijnen voor de behandeling. Nursing Standard, 21, nr. 42, juni 2007, pag. 24-25.

Australië: vergoeding Alimta regionaal bepaald

27-09-2007

Slechts de helft van de Australische asbestslachtoffers met mesothelioom krijgt behandeling met het medicijn Alimta vergoed. Het hangt af van het gebied waarin men woont. Bron: The Advertiser, 29 augustus 2007

Pleuramesothelioom en andere tumoren

27-09-2007

In een Italiaans onderzoek werden bij 32 van 169 mesothelioompatiënten (19%) andere primaire tumoren gevonden. Bij al deze pati&euml.nten was asbestblootstelling aanwijsbaar. De onderzoekers adviseren nader onderzoek naar gemeenschappelijke oorzaken van maligne mesothelioom en bepaalde andere tumoren. Bron: Bianchi, C & T. , (2007). Malignant mesothelioma of the pleura and other malignancies in the same patient. Tumori, 93, 19-22.

Bianchi, C &amp. T. , (2007). Malignant mesothelioma of the pleura and other malignancies in the same patient. Tumori, 93, 19-22.

Aims and background: The co-existence of mesothelioma, mostly asbestos-related, and other primary malignancies has repeatedly been reported. The present study evaluated the frequency of such an occurrence. Methods: In the period October 1979-June 2002, 215 cases of malignant pleural mesothelioma were diagnosed at the Hospital of Monfalcone, Italy. All the cases of the above series, examined at necropsy (169), were included in the study. Occupational histories had been obtained from the patients or from their relatives by personal or telephone interviews. In 132 cases, asbestos bodies were isolated after chemical digestion of lung samples. The thoracic cavities were examined for pleural plaques. Results: Additional malignancies were observed in 32 cases (18.9%). Multiple tumors were synchronous in 22 cases, metachronous in 8 cases, and synchronous and metachronous in 2. Four different tumors were found in 2 cases, 3 malignancies were detected in 6 patients, and 2 malignancies in the remaining 24. The most frequent additional malignancies were prostate adenocarcinoma (7 cases), non-Hodgkin lymphoma or chronic lymphocytic leukaemia (5 cases), bladder carcinoma (4 cases), kidney carcinoma (4 cases), large bowel carcinoma (4 cases), and liver cell carcinoma (4 cases). All the patients had histories of exposure to asbestos, mostly in shipbuilding. Lung asbestos body burdens ranged between 60 and 230,000 per gram of dried tissue. Pleural plaques were found in 26 cases. Conclusions: In contrast with other series of the literature, in the present cases the co-existence of mesothelioma and other malignancies appeared as a relatively frequent event. The lack of a control group does not allow definite conclusions about the meaning of the occurrence. However, the co-existence of certain tumors with asbestos-related mesothelioma suggests that mesothelioma and associated malignancies might share some etiologic factors (asbestos and others)

Verenigd Koninkrijk: medicijn Alimta toch vergoed

18-07-2007

De Britse gezondheidsautoriteit NICE is teruggekomen op een eerdere uitspraak dat het medicijn Alimta niet door de National Health Service (NHS) vergoed zou moeten worden. Een jaar geleden oordeelde NICE dat er niet genoeg bewijs was dat behandeling met dit medicijn beter werkt dan voordeliger behandelingen. Artsen, patiëntengroepen en farmaceut Ei Lily gingen tegen deze uitspraak in beroep. Nu wordt in een richtlijn vermeld dat chemotherapeutische behandeling met een combinatie van Alimta en Cisplatine aanbevolen is en door de NHS moet worden vergoed. Bron: The Times, 9 juli 2007.

Schotse gezondheidsdienst nalatig in voorlichting mesothelioom

10-07-2007

Een Schotse gezondheidsdienst heeft verzuimd een mesothelioompatiënt te informeren over de mogelijkheden van schadevergoeding en aan welke voorwaarden daarvoor moet worden voldaan. Het slachtoffer overleed drie maanden na diagnose zonder dat aan de voorwaarde van een biopsie ter herbeoordeling van de diagnose was voldaan. Pas na zijn dood hoorde zijn vrouw over de mogelijkheden om in aanmerking te komen voor een schadevergoeding. De Schotse ombudsman Publieke Diensten oordeelt dat de Gezondheidsdienst excuses moet aanbieden aan de weduwe. Bron: The Herald, 21 juni 2007.

Biomerkers voor mesothelioom

27-06-2007

Biomerkers als Soluble mesothelin-related peptide (SMRP), osteopontine en megakaryocyte potentiating factor (MPF) zijn nog niet voldoende accuraat om cytohistologie als gouden standaard voor de diagnose van maligne mesothelioom te vervangen. Aldus een overzichtsartikel en een onderzoeksverslag. Biomerkers zijn eiwitten in het bloed die iets kunnen zeggen over de aanwezigheid of verloop van sommige ziektes. Bron: Scherpereel, A. &amp. Lee, G. (2007). Biomarkers for mesothelioma. Current Opinion in Pulmonary Medicine 2007, 13:339. Grigoriu, B.D. et al., (2007). Utility of Osteopontin and SerumMesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment. Clin Cancer Res 13 (10), may 15, p 2928-35-343.
Scherpereel, A. &amp. Lee, G. (2007). Biomarkers for mesothelioma. Current Opinion in Pulmonary Medicine 2007, 13:339-343.

Purpose of review


Mesothelioma is an incurable cancer and its global incidence continues to increase. There has been strong interest in the search for a biomarker that would be of value for the diagnosis, prognosis and disease monitoring of mesothelioma. Large series evaluating the use of novel candidate markers have recently been published.

Recent findings

To date, global gene profiling studies have failed to find a molecule that reliably captures all subtypes of mesothelioma, and differentiates it from benign pathologies and metastatic carcinomas. Soluble mesothelin-related peptide (SMRP), osteopontin and megakaryocyte potentiating factor have been assessed as markers. SMRP testing is clinically available and provides reasonable diagnostic sensitivity and specificity when applied to serum or pleural fluid. Elevated SMRP levels can occur in metastatic, especially ovarian and pancreatic, adenocarcinomas. False negatives are common with sarcomatoid mesothelioma. SMRP levels may reflect tumor load and disease progression. The role of SMRP in predicting mesothelioma development in subjects exposed to asbestos has raised interest. Osteopontin lacks specificity as a diagnostic marker for mesothelioma but may have value in disease monitoring.

Summary

The proposed markers have insufficient accuracy to replace cytohistology as the gold standard for diagnosis for mesothelioma. Elevated SMRP levels raise suspicion of mesothelioma although negative values do not exclude disease. Its role in disease monitoring in patients and in predicting disease development in at-risk individuals warrant further study.



Grigoriu, B.D. et al., (2007). Utility of Osteopontin and SerumMesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment. Clin Cancer Res 13 (10), may 15, p 2928-35

Abstract

Purpose:
Malignant mesothelioma is a highly aggressive tumor and is often diagnosed too late for a curative treatment.We compared diagnostic and prognostic values ofmesothelin and osteopontin in172 patients suspected ofmalignant pleuralmesothelioma (MPM) and in a control group

of 112 asymptomatic asbestos-exposed subjects.

Experimental Design: Osteopontin and mesothelin were assayed with commercial ELISA kits in a series of 43 patients with pleural metastases of various carcinomas, 33 patients with benign pleural lesions associated with asbestos exposure, 96 patients with MPMs, and 112 asbestos-exposed healthy subjects. Results were correlated with patient’s diagnosis and survival.

Results: Serumosteopontin level was higher in MPMpatients compared with healthy asbestos exposed subjects and had a good capability to distinguish between these two populations. However, osteopontin was unable to distinguish between MPM and pleural metastatic carcinoma or benign pleural lesions associated with asbestos exposure. Neither plasma nor pleural fluid osteopontin were more powerful in this respect. Serum mesothelin had a good ability for diagnosing MPM but was unable to identify patients with nonepithelioid mesothelioma subtypes. Survival analysis identified tumor histologic subtype along with serum osteopontin and serum mesothelin as independent prognostic factors in mesothelioma patients.

Conclusions: Osteopontin has a lower diagnostic accuracy than mesothelin in patients suspected of MPM. Insufficient specificity limits osteopontin utility as diagnosticmarker. Bothmolecules have a potential value as prognostic markers.


8ste bijeenkomst International Mesothelioma Interest Group

19-06-2007

Deskundigen analyseren in het blad Oncogene de meest interessante presentaties die gegeven werden op de 8ste bijeenkomst van de International Mesothelioma Interest Group (IMIG). een groep medici met bijzondere belangstelling voor de ziekte maligne mesothelioom. Zij concluderen dat op dit moment operatieve verwijdering van de tumor in combinatie met andere behandelvormen (multimodale therapie) de beste kansen op lange termijn overleving geven. Bron: Carbone, M. et al. (2007). Eighth International Mesothelioma Interest Group. Oncogene advance online publication, 14 may 2007. doi:10.1038/sj.onc.1210515.
Carbone, M. et al. (2007). Eighth International Mesothelioma Interest Group. Oncogene advance online publication, 14 may 2007. doi:10.1038/sj.onc.1210515.

Abstract

The eighth International Mesothelioma Interest Group (IMIG) meeting was held in Chicago, IL, United States, in 19-22 October 2006 to discuss mesothelioma & the cancer often linked to asbestos exposure. It is a very

aggressive malignancy with a median survival of less than 1 year from diagnosis. Millions of people have been exposed worldwide to asbestos, especially during the second half of the twentieth century when asbestos use increased significantly. The tons of asbestos utilized in the past remain a health hazard for current and future generations because asbestos is difficult to be disposed off. This makes asbestos and mesothelioma research a public health issue in addition to a medical problem. Moreover, the very high costs of asbestos litigation have a significant impact on the whole economy. In the United States, up until 2001, defendant companies had paid 54 billion dollars in claims and estimated future liabilities ranged from 145 to 210 billion. Therefore, asbestos research is of great interest to a large audience that includes patients, millions of asbestos-exposed individuals, scientists, physicians,

public health officials, politicians, unions of asbestos workers, lawyers and the public at large. During the past few years, there has been significant progress in understanding the process of mineral fiber carcinogenesis

and mesothelioma pathogenesis. With improved understanding of the pathogenesis of mesothelioma, new diagnostic, preventive and therapeutic options are being developed. A total of 247 papers were presented at the IMIG: the abstracts of these presentations were published in Lung Cancer, Supplement 1, October 2006. Here, experts in different disciplines critically review some of the most exciting presentations of the IMIG meeting. The result is a comprehensive review of the research field of asbestos carcinogenesis and mesothelioma, and of the progress that has been made in recent years in both basic and clinical sciences.

Talkpoeder veilig middel tegen vocht achter de longen

30-05-2007

Talkpoeder kan veilig worden ingezet om mensen te verlossen van vocht achter de longen. Voorwaarde is wel dat de poederdeeltjes niet te klein zijn, aldus hoofdonderzoeker dr. J.P. Janssen, longarts in het Canisius-Wilhelmina Ziekenhuis in Nijmegen. Vocht achter de longen komt o.a. voor bij mensen met longvlieskanker (mesothelioom). Met de talkpoedertechniek laat men de longvliezen verkleven met de binnenkant van de borstwand, zodat er geen ruimte meer is voor het vocht. Bron: Janssen, J.P. et al. (2007). Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study. Lancet, may 5.369(9572):1535-9.
Janssen JP, Collier G, Astoul P, Tassi GF, Noppen M, Rodriguez-Panadero F, Loddenkemper R, Herth FJ, Gasparini S, Marquette CH, Becke B, Froudarakis ME, Driesen P, Bolliger CT, Tschopp JM., (2007). Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study. Lancet. 2007 May 5.369(9572):1535-9.

ABSTRACT

BACKGROUND: Talc is the most effective chemical pleurodesis agent for patients with malignant pleural effusion. However, concerns have arisen about the safety of intrapleural application of talc, after reports of development of acute respiratory distress syndrome in 1-9% of treated patients. Our aim was to establish whether use of large-particle-size talc is safe in patients with malignant pleural effusion.

METHODS: We did a multicentre, open-label, prospective cohort study of 558 patients with malignant pleural effusion who underwent thoracoscopy and talc poudrage with 4 g of calibrated French large-particle talc in 13 European hospitals, and one in South Africa. The primary endpoint was the occurrence of acute respiratory distress syndrome after talc pleurodesis.

FINDINGS: No patients developed acute respiratory distress syndrome (frequency 0%, one-sided 95% CI 0-0.54%). 11 (2%) patients died within 30 days. Additionally, seven patients had non-fatal post-thoracoscopy complications (1.2%), including one case of respiratory failure due to unexplained bilateral pneumothorax.

INTERPRETATION: Use of large-particle talc for pleurodesis in malignant pleural effusion is safe, and not associated with the development of acute respiratory distress syndrome.

Asbestafval fabriek beschadigt waterplant

30-05-2007

De hoeveelheid anti-oxidant enzym gluthatione in eendenkroos neemt af bij contact met chrysotiel (wit) asbest. De asbest was afkomstig uit een asbestcementfabriek. Meting van de hoeveelheid anti-oxidanten in waterplanten als eendenkroos kan een methode zijn om de milieuschade van blootstelling aan asbest te meten. Bron: Trivedi, A.K., et. al. (2007). Environmental Contamination of Chrysotile Asbestos and Its Toxic Effects on Antioxidative System of Lemna gibba. Archives of Environmental Contamination and Toxicology 52, 355-362.
Trivedi, A.K., et. al. (2007). Environmental Contamination of Chrysotile Asbestos and Its Toxic Effects on Antioxidative System of Lemna gibba. Archives of Environmental Contamination and Toxicology 52, 355-362.

Abstract.

Asbestos was monitored in various plant samples around an asbestos cement factory. Asbestos residue was found on the surface of all plant samples monitored. Based on asbestos concentration found in different plant samples during monitoring and on the property of asbestos to cause reactive oxygen species-mediated oxidative stress in animal models, laboratory experiments were conducted to assess the toxicity of chrysotile asbestos on an aquatic macrophyte, duckweed

(Lemna gibba.). L. gibba plants were exposed to four concentrations (0.5, 1.0, 2.0, and 5.0 lg/mL) of chrysotile asbestos under laboratory conditions, and alterations in the glutathione and ascorbate antioxidative system were estimated at postexposure days 7, 14, 21, and 28 in order to assess changes in their level as suitable biomarkers of chrysotile contamination. Chrysotile exposure caused a decrease in total and reduced glutathione and an enhancement in the oxidized glutathione as well as the reduced/oxidized glutathione ratio. An increase in ascorbate pool size, and reduced as well as oxidized ascorbate was found to be accompanied by a decrease in the ratio of reduced/oxidized ascorbate. Alteration in the glutathione and ascorbate level might be considered as a biomarker of exposure to an unsafe environment because these are essential compounds of the general antioxidative strategy to overcome oxidative stress due to environmental constraints. Because an increase in the oxidation rate of antioxidants weakens cellular defenses and indicates a precarious state, they could constitute

indicators of toxicity.

SV-40 virus en asbest samen schadelijker bij muizen

30-05-2007

Een studie bij aan asbest blootgestelde muizen laat zien dat het sv-40 virus de ontwikkeling van mesothelioom stimuleert. De manier waarop is nog niet duidelijk. Het lijkt erop dat het virus de werking van het p-53 gen stopt: een gen dat de ontwikkeling van tumoren onderdrukt. Bron: Pietruska, J.R. & Kane, A.B., (2007). SV40 Oncoproteins Enhance Asbestos-Induced DNA Double-Strand Breaks and Abrogate Senescence in Murine Mesothelial Cells. Cancer Res, 67 (8), april 15, 3637-45.
Pietruska, J.R. & Kane, A.B., (2007). SV40 Oncoproteins Enhance Asbestos-Induced DNA Double-Strand Breaks and Abrogate Senescence in Murine Mesothelial Cells. Cancer Res, 67 (8), april 15, 3637-45.

Abstract

SV40 virus has emerged as a potential cofactor with asbestos in the development of diffuse malignant mesothelioma, but its precise role in the pathogenesis of this tumor is unclear. SV40

large T antigen is known to inactivate cellular proteins involved in DNA damage and senescence, including p53 and pRb. We hypothesize that SV40 oncoproteins will sensitize mesothelial cells to DNA damage induced by asbestos or chemotherapeutic agents. SV40 oncoprotein expression in murine mesothelial cell lines enhanced spontaneous and asbestos-induced double-strand breaks, indicated by .-H2AX foci, and potentiated micronucleus formation. Mesothelial cells exposed to asbestos or bleomycin for 96 h acquired senescent-like morphology and displayed elevated senescence associated

B-galactosidase activity, reduced bromodeoxyuridine (BrdUrd) incorporation, and reduced colony formation. SV40 oncoprotein expression abrogated the senescent phenotype,

and transfected cell lines showed an increase in both BrdUrd incorporation and colony formation after prolonged DNA damage. Murine mesothelial cell lines lacking wild-type p53 due to a point mutation or gene rearrangement also failed to senesce in response to asbestos or chemotherapeutic agents. In addition, stress-induced senescence in human mesothelial cell lines was impaired by SV40 oncoprotein

expression (MeT-5A), p53 small interfering RNA, or spontaneous p53 mutation (REN). These studies suggest that exposure to DNA-damaging agents can induce senescence in both murine and human mesothelioma cell lines and suggest a major, although not exclusive, role for p53 in this response.

SV40 virus may contribute to mesothelioma progression by impairing stress-induced senescence, in part through p53 inactivation, thereby favoring survival and proliferation of

mesothelial cells that have sustained DNA damage. [Cancer Res 2007.67(8):3637-45